These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 22787120

  • 1. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.
    Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, Lu J, Huang B.
    Cancer Res; 2012 Sep 01; 72(17):4597-608. PubMed ID: 22787120
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition.
    Ruan H, Yang H, Wei H, Xiao W, Lou N, Qiu B, Xu G, Song Z, Xiao H, Liu L, Zhou Y, Hu W, Chen K, Chen X, Zhang X.
    Int J Oncol; 2017 Jul 01; 51(1):336-346. PubMed ID: 28534986
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. SOX4: Joining the Master Regulators of Epithelial-to-Mesenchymal Transition?
    Lourenço AR, Coffer PJ.
    Trends Cancer; 2017 Aug 01; 3(8):571-582. PubMed ID: 28780934
    [Abstract] [Full Text] [Related]

  • 8. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P.
    Cancer Res; 2006 Feb 15; 66(4):2202-9. PubMed ID: 16489022
    [Abstract] [Full Text] [Related]

  • 9. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G.
    Cancer Res; 2007 Sep 15; 67(18):8742-51. PubMed ID: 17875715
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer.
    Juang YL, Jeng YM, Chen CL, Lien HC.
    Mol Carcinog; 2016 Dec 15; 55(12):2247-2259. PubMed ID: 26824226
    [Abstract] [Full Text] [Related]

  • 12. SOX4 is associated with poor prognosis in cholangiocarcinoma.
    Wang W, Zhang J, Zhan X, Lin T, Yang M, Hu J, Han B, Hu S.
    Biochem Biophys Res Commun; 2014 Sep 26; 452(3):614-21. PubMed ID: 25181339
    [Abstract] [Full Text] [Related]

  • 13. SHON, a novel secreted protein, regulates epithelial-mesenchymal transition through transforming growth factor-β signaling in human breast cancer cells.
    Li L, Liu DX, Zhang N, Liang Q, Feng J, Yao M, Liu J, Li X, Zhang Y, Lu J, Huang B.
    Int J Cancer; 2015 Mar 15; 136(6):1285-95. PubMed ID: 25082541
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. SOX4 induces tumor invasion by targeting EMT-related pathway in prostate cancer.
    Liu Y, Zeng S, Jiang X, Lai D, Su Z.
    Tumour Biol; 2017 May 15; 39(5):1010428317694539. PubMed ID: 28466783
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.